Check the time stamp on this data. Updated AI-Generated Signals for Denali Therapeutics Inc. (DNLI) available here: DNLI.

Denali Therapeutics (DNLI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Denali Therapeutics (DNLI) announced initiation of dosing in a global Phase 2a clinical study, BEACON, of the investigational drug leucine-rich ...

Pitcairn Co. purchased a new position in Denali Therapeutics Inc. (NASDAQ:DNLI – Free Report) during the 3rd quarter, ...

Shares of NASDAQ:DNLI opened at $31.58 on Monday ... institutional investors own 92.92% of the company’s stock. Receive News & Ratings for Denali Therapeutics Daily - Enter your email address ...

Denali Therapeutics shares are moving lower in Thursday's after-hours session after the company announced that its Phase 2 study of oditrasertib was discontinued. Biogen (NASDAQ: BIIB) reported ...

So, the natural question for Denali Therapeutics (NASDAQ:DNLI) shareholders is whether they should be concerned by its rate of cash burn. In this report, we will consider the company's annual ...

Oppenheimer analyst Jay Olson maintained a Buy rating on Denali Therapeutics (DNLI – Research Report) on November 11 and set a price target of $50.00. The company’s shares closed yesterday at ...